Atherothrombotic events in coronary artery disease
Pendopharm, a division of Pharmascience Inc.
NOC Status at Filing:
Manufacturer Requested Reimbursement Criteria1:
For reduction of atherothrombotic events in patients with existing coronary artery disease who had a myocardial infarction.
Reduction of atherothrombotic events in adult patients with existing coronary artery disease, in addition to standard therapies, including LDL-C lowering and antithrombotic drug treatment.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.